It was listed on the London Stock Exchange until it was acquired by American private equity company Clayton, Dubilier & Rice in August 2021.

[10][11] In September 2015, UDG Healthcare sold its Irish drug distribution businesses to McKesson Corporation for $466 million.

[15] In August 2018, UDG Healthcare announced the sale of its Aquilant division to H2 Equity Partners, a European private equity firm, for a total potential net consideration of up to €23 million (approximately $27 million).

[16] The company agreed to be acquired by Clayton, Dubilier & Rice in a £2.8 billion transaction in June 2021.

[17] UDG Healthcare plc operates across two divisions: Ashfield and Sharp.